he Johnson & Johnson Office of the Chief Medical Officer is a global group of medical and scientific professionals focused on advancing evidence- and science-based decision-making that is driven by bioethical principles and values.
Every day, we work to put people first—from proactive and transparent medical safety surveillance, to groundbreaking real-world evidence applications, pediatric clinical research advancements, early access innovation and more.
The company's mission is to care for the world—one person at a time. Just ask Chief Medical Officer Joanne Waldstreicher, M.D., who's been leading the charge to improve the process by which very sick patients may apply for access to investigational medications.
These guidelines are to ensure that human pluripotent stem cell research conducted by Johnson & Johnson conforms to current international standards of scientific and ethical oversight, and that all scientists and employees of the Johnson & Johnson Family of Companies adhere to these ethical principles when conducting human pluripotent stem cell research.
Our Ethical Code for the Conduct of Research and Development is intended to complement our Credo by providing more specific standards of conduct and behavior for physicians, clinical research scientists and others who are responsible for medical aspects of research and development.
We follow five important principles when providing pre-approval access to investigational medicines to patients with serious diseases to access medicines not yet approved by regulatory health authorities.